date,title,source
Nov-13-18,Novus Therapeutics Reports Third Quarter 2018 Financial Results,Business Wire
Nov-15-18,Novus Therapeutics to Present at the 2018 Piper Jaffray Healthcare Conference,Business Wire
Nov-27-18,Novus Therapeutics Doses First Subjects in Phase 1 Study of OP0201,Business Wire
Dec-04-18,Novus Therapeutics Announces Formation of Scientific Advisory Board,Business Wire
Dec-25-18,"Can We See Significant Institutional Ownership On The Novus Therapeutics, Inc. (NASDAQ:NVUS) Share Register?",Simply Wall St.
Jan-08-19,Novus Therapeutics Doses First Patient with Acute Otitis Media in Phase 1 Study of OP0201,Business Wire
Jan-30-19,Novus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials,Business Wire
Feb-11-19,Novus Therapeutics Doses First Subjects in Phase 1 Pharmacodynamics Study of OP0201,Business Wire
Feb-19-19,Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201,Business Wire
Feb-20-19,Novus Therapeutics to Participate in the 8th Annual SVB Leerink Global Healthcare Conference,Business Wire
Mar-28-19,Novus Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Clinical Updates,Business Wire
Apr-22-19,Novus Therapeutics Announces Results of Two Single-Dose OP0201 Phase 1 Clinical Trials,Business Wire
